tetano
Editor, Senior Moderator
PLoS One. 2019 Sep 12;14(9):e0222148. doi: 10.1371/journal.pone.0222148. eCollection 2019.
[h=1]Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice.[/h] Kramskaya T[SUP]1[/SUP], Leontieva G[SUP]1[/SUP], Desheva Y[SUP]2,[/SUP][SUP]3[/SUP], Grabovskaya K[SUP]1[/SUP], Gupalova T[SUP]1[/SUP], Rudenko L[SUP]2[/SUP], Suvorov A[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h] 1 Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation. 2 Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation. 3 Department of Fundamental Medicine and Medical Technologies, Faculty of Dentistry and Medical Technologies, Saint Petersburg State University, Saint Petersburg, Russian Federation.
[h=3]Abstract[/h] Influenza and its bacterial complications are a leading cause of morbidity and mortality worldwide. The effect of combined immunization with live influenza vaccine and recombinant chimeric pneumococcal protein in dual infection caused by influenza H1N1 and S. pneumoniae (serotype 3) has been studied. The combined vaccine consisted of the strain A/California/2009/38 (H1N1) pdm and chimeric recombinant protein PSPF composed of immunodominant fragments of the surface virulence factors of S. pneumoniae-PsaA, PspA, and Shr1875-associated with modified salmonella flagellin. Vaccinated mice were infected with the influenza virus 24 hours before or 24 hours after the onset of pneumococcal infection. The protective effect of combined vaccination was shown on both models of viral-bacterial infection.
PMID: 31513620 DOI: 10.1371/journal.pone.0222148
Free full text
[h=1]Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice.[/h] Kramskaya T[SUP]1[/SUP], Leontieva G[SUP]1[/SUP], Desheva Y[SUP]2,[/SUP][SUP]3[/SUP], Grabovskaya K[SUP]1[/SUP], Gupalova T[SUP]1[/SUP], Rudenko L[SUP]2[/SUP], Suvorov A[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h] 1 Department of Molecular Microbiology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation. 2 Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russian Federation. 3 Department of Fundamental Medicine and Medical Technologies, Faculty of Dentistry and Medical Technologies, Saint Petersburg State University, Saint Petersburg, Russian Federation.
[h=3]Abstract[/h] Influenza and its bacterial complications are a leading cause of morbidity and mortality worldwide. The effect of combined immunization with live influenza vaccine and recombinant chimeric pneumococcal protein in dual infection caused by influenza H1N1 and S. pneumoniae (serotype 3) has been studied. The combined vaccine consisted of the strain A/California/2009/38 (H1N1) pdm and chimeric recombinant protein PSPF composed of immunodominant fragments of the surface virulence factors of S. pneumoniae-PsaA, PspA, and Shr1875-associated with modified salmonella flagellin. Vaccinated mice were infected with the influenza virus 24 hours before or 24 hours after the onset of pneumococcal infection. The protective effect of combined vaccination was shown on both models of viral-bacterial infection.
PMID: 31513620 DOI: 10.1371/journal.pone.0222148
Free full text